As venetoclax is a Bcl-2 inhibitor, it requires an apoptotic trigger to activate its function effectively, suggesting that agents like VPA, which induce Bax and Bak, are suitable partners in AML treatment (Figure 6). Here, BAX is linked to acute myeloid leukemia.